PepTalk - The Protein Science Week

January 14–19, 2019
San Diego, CA, USA

Meet Genedata experts at PepTalk in San Diego, CA, USA.

Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, and quality control of biologicals.

To get more information about Genedata solutions, please contact info@genedata.com.

Recommended Oral Presentations

Platformization of Multi-Specific Protein Engineering: From Handling Complex Data to Bioinformatics Workflow Support for High-Throughput Screening
Norbert Furtmann, PhD, Lab Head, Bioinformatics, High Throughput Biologics, Sanofi-Aventis Deutschland GmbH

Process Technologies & Purification: Bioprocess Data Management
Monday, January 14 | 11:15–11:45 am

As the success rate to identify a multi-specific lead molecule with favorable drug-like properties increases with the number of variants tested, we established a novel, automated platform process for the fast generation of large panels of multi-specific variants (up to 10,000). Here we report on our integrated bioinformatics platform to support and steer our screening process as well as on our tools for analyzing and handling the generated datasets.

Implementation of an Integrated Bioprocess Development Workflow Platform
Matthew Schwartz, MSc, Associate Director, Upstream Process Development, Celgene

Process Technologies & Purification: Bioprocess Data Management
Monday, January 14 | 5:00–5:30 pm

Celgene’s strategy for implementation of a workflow platform for streamlining development activities will be presented. The new system acts as a cross-functional data backbone that integrates all bioprocess development workflows from post-discovery through transfer to manufacturing and will lead to a significant increase in Celgene’s operational efficiency and throughput. It has the capability to capture output data automatically (online, at-line and offline) along the process from various laboratory equipment.

A Platform Approach to Manage Developability and Manufacturability Risks of Biologics Molecules   
Christopher Smith, PhD, Head of US Biologics Business Unit
, Genedata

Protein Engineering & Development: Computational and Analytical Tools for Protein Engineering
Wednesday, January 16 | 9:20–9:50

We present a workflow system that enables very systematic developability and manufacturability assessments from the very early stage to the later stages of the biologics R&D process, using both in silico methods and high throughput analytical confirmatory methods. We show use cases not only for mAbs but also for complex multi/bispecific formats, as well as engineered therapeutic cell lines (e.g., CAR T cells). We also discuss building predictive models for developability utilizing such a system.

Platformization of Multi-Specific Protein Engineering II: From Automated Transfection to High-Throughput Multi-Parametric Characterization of Large Variant Libraries
Joerg Birkenfeld, PhD, Section Head, High Throughput Biologics, R&D Biologics Research/Protein Therapeutics, Sanofi-Aventis Deutschland GmbH

Process Technologies & Purification: Higher-Throughput Protein Production and Characterization
Thursday, January 17 | 9:00–9:30

The success rate to identify a multi-specific lead molecule with favorable drug-like properties increases with the number of engineered variants tested. We recently established a novel, fully automated platform process for the in silico design and fast generation of large panels of multi-specific variants. Here, we report on the integration of miniaturized lab unit operations with cutting-edge automation for transient transfection, expression, purification and characterization of up to 10,000 engineered variants in high-throughput.

Recommended Poster Presentations

Poster Session A
January 14–15

A Platform Approach to Manage Developability and Manufacturability Risks of Biologics Molecules   
Amanda Fitzgerald, Genedata

Design, Generation, and Evaluation of TCR-, TCR mimetic- and CAR-based Therapeutics for Cancer Immunotherapy
Christopher Smith, Genedata

End-to-End Workflow Platform for Integrated Biopharmaceutical Development
Adrienne Craig-Kennard, Genedata

An Automated Approach for Comprehensive Characterization and Quantification of Low-abundance Sequence Variants in a Standard Monoclonal Antibody   
Aude Tartiere, Genedata

Poster Session B
January 15–16

Automated Data Processing and Analysis for Quality Monitoring of Biotherapeutics by Multi-attribute Method (MAM)   
Maurizio Bronzetti, Genedata

Links:
www.chi-peptalk.com